(2014)

Bill No. HB 5203

Amendment No.

## CHAMBER ACTION

Senate House

•

The Conference Committee on HB 5203 offered the following:

1 2

## Conference Committee Amendment (with title amendment)

3

5

6

7

9

10 11

1213

14

1 643063

20.435, Florida Statutes, is amended to read:

trust funds shall be administered by the Department of Health:
 (8) Biomedical Research Trust Fund.
 (a) Funds to be credited to the trust fund shall consist of funds deposited pursuant to s. 215.5601 and any other funds appropriated by the Legislature. Funds shall be used for the

20.435 Department of Health; trust funds.—The following

Remove everything after the enacting clause and insert:

Section 1. Paragraph (a) of subsection (8) of section

Program, the Florida Consortium of National Cancer Institute

purposes of the James and Esther King Biomedical Research

Approved For Filing: 4/30/2014 7:36:33 PM Page 1 of 10

```
15
    Centers Program, and the William G. "Bill" Bankhead, Jr., and
16
    David Coley Cancer Research Program as specified in ss.
17
    215.5602, 288.955, 381.915, and 381.922. The trust fund is
    exempt from the service charges imposed by s. 215.20.
18
         Section 2. Paragraph (a) of subsection (12) of section
19
20
    215.5602, Florida Statutes, is amended to read:
21
         215.5602 James and Esther King Biomedical Research
22
    Program.-
23
                 Beginning in the 2011-2012 fiscal year and
         (12)(a)
24
    thereafter, $25 million from the revenue deposited into the
25
    Health Care Trust Fund pursuant to ss. 210.011(9) and 210.276(7)
26
    shall be reserved for research of tobacco-related or cancer-
27
    related illnesses. Of the revenue deposited in the Health Care
    Trust Fund pursuant to this section, $25 million shall be
28
29
    transferred to the Biomedical Research Trust Fund within the
    Department of Health. Subject to annual appropriations in the
30
31
    General Appropriations Act, $5 million shall be appropriated to
32
    the James and Esther King Biomedical Research Program, $5
33
    million shall be appropriated to the William G. "Bill" Bankhead,
34
    Jr., and David Coley Cancer Research Program created under s.
    381.922, $5 million shall be appropriated to the H. Lee Moffitt
35
    Cancer Center and Research Institute established under s.
36
37
    1004.43, $5 million shall be appropriated to the Sylvester
38
    Comprehensive Cancer Center of the University of Miami, and $5
39
    million shall be appropriated to the Shands Cancer Hospital.
```

643063

40

Section 3. Section 381.915, Florida Statutes, is created

41 to read:

- 381.915 Florida Consortium of National Cancer Institute
  Centers Program.—
- (1) This section may be cited as the "Florida NCI Cancer Centers Act."
- (2) The Florida Consortium of National Cancer Institute

  Centers Program is established to enhance the quality and

  competitiveness of cancer care in this state, further a

  statewide biomedical research strategy directly responsive to

  the health needs of Florida's citizens, and capitalize on the

  potential educational opportunities available to its students.

  The department shall make payments to Florida-based cancer

  centers recognized by the National Cancer Institute (NCI) at the

  National Institutes of Health as NCI-designated cancer centers

  or NCI-designated comprehensive cancer centers, and cancer

  centers working toward achieving NCI designation. The department

  shall distribute funds to participating cancer centers on a

  quarterly basis during each fiscal year for which an

  appropriation is made.
- (3) On or before September 15 of each year, the department shall calculate an allocation fraction to be used for distributing funds to participating cancer centers. On or before the final business day of each quarter of the state fiscal year, the department shall distribute to each participating cancer center one-fourth of that cancer center's annual allocation calculated under subsection (6). The allocation fraction for

Approved For Filing: 4/30/2014 7:36:33 PM

each participating cancer center is based on the cancer center's tier-designated weight under subsection (4) multiplied by each of the following allocation factors: number of reportable cases, peer-review costs, and biomedical education and training. As used in this section, the term:

- (a) "Biomedical education and training" means instruction that is offered to a student who is enrolled in a biomedical research program at an affiliated university as a medical student or a student in a master's or doctoral degree program, or who is a resident physician trainee or postdoctoral trainee in such program. An affiliated university biomedical research program must be accredited or approved by a nationally recognized agency and offered through an institution accredited by the Commission on Colleges of the Southern Association of Colleges and Schools. Full-time equivalency for trainees shall be prorated for training received in oncologic sciences and oncologic medicine.
- (b) "Cancer center" means a freestanding center, a center situated within an academic institution, or a formal research-based consortium under centralized leadership that has achieved NCI designation or is prepared to achieve NCI designation by July 1, 2019.
- (c) "Florida-based" means that a cancer center's actual or sought designated status is or would be recognized by the NCI as primarily located in Florida and not in another state.

	(d)	"Peer	-review	costs"	means	the	total	annual	dire	<u>ct</u>
costs	for	peer-	reviewed	d cance:	r-rela	ted :	resear	ch proje	ects,	
consi	ster	nt with	report	ing gui	delines	s pro	ovided	by the	NCI,	for
the m	nost	recent	annual	report	ing pe	riod	availa	able.		

- (e) "Reportable cases" means cases of cancer in which a cancer center is involved in the diagnosis, evaluation of the diagnosis, evaluation of the extent of cancer spread at the time of diagnosis, or administration of all or any part of the first course of therapy for the most recent annual reporting period available. Cases relating to patients enrolled in institutional or investigator-initiated interventional clinical trials shall be weighted at 1.2 relative to other cases weighted at 1.0.

  Determination of institutional or investigator-initiated interventional clinical trials must be consistent with reporting quidelines provided by the NCI.
- (4) Tier designations and corresponding weights within the Florida Consortium of National Cancer Institute Centers Program are as follows:
- (a) Tier 1: Florida-based NCI-designated comprehensive cancer centers, which shall be weighted at 1.5.
- (b) Tier 2: Florida-based NCI-designated cancer centers, which shall be weighted at 1.25.
- (c) Tier 3: Florida-based cancer centers seeking

  designation as either a NCI-designated cancer center or NCI
  designated comprehensive cancer center, which shall be weighted at 1.0.

Approved For Filing: 4/30/2014 7:36:33 PM

	<u>1.</u>	А	canc	cer	center	shall	meet	the	e foli	lot	ving minimum		
crit	eria	to	be	cor	nsidered	d elig	ible	for	Tier	3	designation	in	any
give	n fi	sca	l ye	ear:	:								

- <u>a. Conducting cancer-related basic scientific research and</u> cancer-related population scientific research;
- b. Offering and providing the full range of diagnostic and treatment services on site, as determined by the Commission on Cancer of the American College of Surgeons;
- c. Hosting or conducting cancer-related interventional clinical trials that are registered with the NCI's Clinical Trials Reporting Program;
- d. Offering degree-granting programs or affiliating with universities through degree-granting programs accredited or approved by a nationally recognized agency and offered through the center or through the center in conjunction with another institution accredited by the Commission on Colleges of the Southern Association of Colleges and Schools;
- e. Providing training to clinical trainees, medical trainees accredited by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association, and postdoctoral fellows recently awarded a doctorate degree; and
- f. Having more than \$5 million in annual direct costs associated with their total NCI peer-reviewed grant funding.
- 2. The General Appropriations Act or accompanying legislation may limit the number of cancer centers which shall

143	receive Tier 3 designations or provide additional criteria for
144	such designation.
145	3. A cancer center's participation in Tier 3 shall be
146	limited to 5 years.
147	4. A cancer center that qualifies as a designated Tier 3
148	center under the criteria provided in subparagraph 1. by July,
149	1, 2014, is authorized to pursue NCI designation as a cancer
150	center or a comprehensive cancer center for 5 years after
151	qualification.
152	(5) The department shall use the following formula to
153	calculate a participating cancer center's allocation fraction:
154	
155	$CAF = [0.4 \times (CRC \div TCRC)] + [0.3 \times (CPC \div TCPC)] + [0.3 \times (CBE \div TCBE)]$
156	
157	Where:
158	CAF=A cancer center's allocation fraction.
159	CRC=A cancer center's tier-weighted reportable cases.
160	TCRC=The total tier-weighted reportable cases for all
161	cancer centers.
162	CPC=A cancer center's tier-weighted peer-review costs.
163	TCPC=The total tier-weighted peer-review costs for all
164	cancer centers.
165	CBE=A cancer center's tier-weighted biomedical education

643063

and training.

166

167

168

Approved For Filing: 4/30/2014 7:36:33 PM

training for all cancer centers.

TCBE=The total tier-weighted biomedical education and

- (6) A cancer center's annual allocation shall be calculated by multiplying the funds appropriated for the Florida Consortium of National Cancer Institute Centers Program in the General Appropriations Act by that cancer center's allocation fraction. If the calculation results in an annual allocation that is less than \$16 million, that cancer center's annual allocation shall be increased to a sum equaling \$16 million, with the additional funds being provided proportionally from the annual allocations calculated for the other participating cancer centers.
- (7) Beginning July 1, 2017, and every 3 years thereafter, the department, in conjunction with participating cancer centers, shall submit a report to the Cancer Control and Research Advisory Council on specific metrics relating to cancer mortality and external funding for cancer-related research in the state. If a cancer center does not endorse this report or produce an equivalent independent report, the cancer center shall be suspended from the program for 1 year. The report must include:
- (a) An analysis of trending age-adjusted cancer mortality rates in the state, which must include, at a minimum, overall age-adjusted mortality rates for cancer statewide and age-adjusted mortality rates by age group, geographic region, and type of cancer, which must include, at a minimum:
  - 1. Lung cancer.

Approved For Filing: 4/30/2014 7:36:33 PM

Page 8 of 10

195 2. Pancreatic cancer.

196	3. Sarcoma.
197	4. Melanoma.
198	5. Leukemia and myelodysplastic syndromes.
199	6. Brain cancer.
200	(b) Identification of trends in overall federal funding,
201	broken down by institutional source, for cancer-related research
202	in the state.
203	(c) A list and narrative description of collaborative
204	grants and interinstitutional collaboration among participating
205	cancer centers, a comparison of collaborative grants in
206	proportion to the grant totals for each cancer center, a
207	catalogue of retreats and progress seed grants using state
208	funds, and targets for collaboration in the future and reports
209	on progress regarding such targets where appropriate.
210	(8) This section is subject to annual appropriation by the
211	Legislature.
212	(9) The department may adopt rules to administer this
213	section.
214	Section 4. This act shall take effect July 1, 2014.
215	
216	
217	TITLE AMENDMENT
218	Remove everything before the enacting clause and insert:
219	A bill to be entitled

643063

Approved For Filing: 4/30/2014 7:36:33 PM

Page 9 of 10

An act relating to cancer centers; amending s. 20.435,
F.S.; authorizing funds in the Biomedical Research
Trust Fund to be used for the Florida Consortium of
National Cancer Institute Centers Program; amending s.
215.5602, F.S.; revising the distribution of certain
funds deposited into the Biomedical Research Trust
Fund; creating s. 381.915, F.S.; providing a short
title; establishing the Florida Consortium of National
Cancer Institute Centers Program; providing purpose;
requiring the Department of Health to distribute
funding to certain cancer centers; providing a formula
for determination of allocations; providing
definitions; providing criteria for designation of
tiers for cancer centers; requiring reports; providing
that funding is subject to annual appropriation;
providing rulemaking authority; providing an effective
date.